Mesenchymal stem cell

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Mesoblast Limited (MESO)

Retrieved on: 
Wednesday, November 4, 2020
Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Cell biology, Regenerative biomedicine, Mesoblast, Cell therapy, Mesenchymal stem cell, Mesenchyme, Prochymal

Mesoblast develops allogeneic cellular medicines using its proprietary mesenchymal lineage cell therapy platform.

Key Points: 
  • Mesoblast develops allogeneic cellular medicines using its proprietary mesenchymal lineage cell therapy platform.
  • Its lead product candidate, RYONCIL (remestemcel-L), is an investigational therapy comprising mesenchymal stem cells derived from bone marrow.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
  • Glancy Prongay & Murray LLP, Los Angeles

Therapeutic Solutions International Identifies New Mechanism of Mesenchymal Stem Cell Treatment of Brain Injury

Retrieved on: 
Tuesday, October 27, 2020
Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Induced stem cells, Cell biology, Developmental biology, Immunotherapy, Mesenchymal stem cell, Stem cell secretome, Adult stem cell

In a series of laboratory and animal experiments, the Company demonstrated that mesenchymal stem cells produce therapeutic factors that block the opening of brain blood vessels after trauma occurs to the brain.

Key Points: 
  • In a series of laboratory and animal experiments, the Company demonstrated that mesenchymal stem cells produce therapeutic factors that block the opening of brain blood vessels after trauma occurs to the brain.
  • By identifying specific stem cells and concentrations of stem cells, the Company believes it has discovered a "therapeutic window" for treatment of multiple types of brain injury.
  • "Our scientific team is laser focused on preparing our IND for utilizing the clinical stage mesenchymal stem cell, JadiCell for treatment of CTE.
  • Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases.

Catalent and BrainStorm Cell Therapeutics Announce Partnership for the Manufacture of Mesenchymal Stem Cell Platform Therapy NurOwn®

Retrieved on: 
Thursday, October 22, 2020
Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Mesenchymal stem cell, Catalent, Adult stem cell, Artemin, Neurotrophic factors

NurOwn induces mesenchymal stem cells (MSCs) to secrete high levels of neurotrophic factors (NTFs) known to promote the survival of neurons and neuroprotection.

Key Points: 
  • NurOwn induces mesenchymal stem cells (MSCs) to secrete high levels of neurotrophic factors (NTFs) known to promote the survival of neurons and neuroprotection.
  • We are proud to have a partner in Catalent whose excellence in manufacturing quality therapies will support commercial supply of NurOwn, said Chaim Lebovits, Chief Executive Officer of BrainStorm Cell Therapeutics.
  • If NurOwn is successful in the current clinical trials, this agreement will be integral to ensuring rapid access for patients.
  • About BrainStorm Cell Therapeutics Inc.
    BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Mesoblast Limited (MESO)

Retrieved on: 
Thursday, October 15, 2020
Legal, Professional services, Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Cell biology, Regenerative biomedicine, Mesoblast, Cell therapy, Mesenchymal stem cell

Glancy Prongay & Murray LLP (GPM) reminds investors of the upcoming December 7, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Mesoblast Limited (Mesoblast or the Company) (NASDAQ: MESO ) securities between April 16, 2019 and October 1, 2020, inclusive (the Class Period).

Key Points: 
  • Glancy Prongay & Murray LLP (GPM) reminds investors of the upcoming December 7, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Mesoblast Limited (Mesoblast or the Company) (NASDAQ: MESO ) securities between April 16, 2019 and October 1, 2020, inclusive (the Class Period).
  • Mesoblast develops allogeneic cellular medicines using its proprietary mesenchymal lineage cell therapy platform.
  • Its lead product candidate, RYONCIL (remestemcel-L), is an investigational therapy comprising mesenchymal stem cells derived from bone marrow.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

MESO CLASS ACTION NOTICE: The Law Offices of Frank R. Cruz Files Securities Fraud Lawsuit Against Mesoblast Limited (MESO)

Retrieved on: 
Friday, October 9, 2020
Legal, Professional services, Branches of biology, Biology, Life sciences, Stem cells, Regenerative biomedicine, Mesoblast, Biotechnology, Cell biology, Induced stem cells, Mesenchymal stem cell, Bone marrow

The Law Offices of Frank R. Cruz announces that it has filed a class action lawsuit in the United States District Court for the Southern District of New York, captioned Kristal v. Mesoblast Limited, et al., (Case No.

Key Points: 
  • The Law Offices of Frank R. Cruz announces that it has filed a class action lawsuit in the United States District Court for the Southern District of New York, captioned Kristal v. Mesoblast Limited, et al., (Case No.
  • 1:20-cv-08430), on behalf of persons and entities that purchased or otherwise acquired Mesoblast Limited ("Mesoblast" or the "Company") (NASDAQ: MESO ) securities between April 16, 2019 and October 1, 2020, inclusive (the "Class Period").
  • Its lead product candidate, RYONCIL (remestemcel-L), is an investigational therapy comprising mesenchymal stem cells derived from bone marrow.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

MESOBLAST ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Mesoblast Limited and Encourages Investors to Contact the Firm

Retrieved on: 
Friday, October 9, 2020
Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Cell biology, Regenerative biomedicine, Mesoblast, Mesenchymal stem cell, Cell therapy, Draft:Ryoncil, Remestemcel-L, Prochymal

Investors have until December 7, 2020 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until December 7, 2020 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • Mesoblast develops allogeneic cellular medicines using its proprietary mesenchymal lineage cell therapy platform.
  • Its lead product candidate, RYONCIL (remestemcel-L), is an investigational therapy comprising mesenchymal stem cells derived from bone marrow.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

BrainStorm Cell Therapeutics to Announce Third Quarter Financial Results and Provide a Corporate Update

Retrieved on: 
Friday, October 2, 2020
Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Developmental biology, Cell biology, Mesenchymal stem cell, Adult stem cell, Cellular differentiation, Induced stem cells, Stem-cell therapy

MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo.

Key Points: 
  • MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo.
  • MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors (NTFs).
  • BrainStorm has fully enrolled a Phase 3 pivotal trial of autologous MSC-NTF cells for the treatment of amyotrophic lateral sclerosis (ALS).
  • BrainStorm Cell Therapeutics Inc.is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases.

BAYLX, INC. Receives US FDA Clearance of COVID-19 IND Application For Umbilical Cord Tissue Mesenchymal Stem Cells Product

Retrieved on: 
Wednesday, September 30, 2020
Research, Infectious diseases, FDA, Clinical trials, Stem cells, Biotechnology, Health, Pharmaceutical, Science, Life sciences, Biology, Branches of biology, Biotechnology, Stem cells, Mesenchymal stem cell, Investigational New Drug, Biopharmaceutical, Mesoblast, Stem-cell therapy

Baylx, Inc. (Baylx), a clinical-stage stem cell biopharmaceutical company focused on developing living stem cell products to address unmet medical needs, announced that the U.S. Food and Drug Administration (FDA) has cleared Baylx's Investigational New Drug (IND) application for BX-U001, a fresh, non-frozen human umbilical cord tissue mesenchymal stem cells (hUC-MSC) product in patients with COVID-19.

Key Points: 
  • Baylx, Inc. (Baylx), a clinical-stage stem cell biopharmaceutical company focused on developing living stem cell products to address unmet medical needs, announced that the U.S. Food and Drug Administration (FDA) has cleared Baylx's Investigational New Drug (IND) application for BX-U001, a fresh, non-frozen human umbilical cord tissue mesenchymal stem cells (hUC-MSC) product in patients with COVID-19.
  • Mesenchymal stem cells hold great promise to treat COVID-19 patients due to their potential in inhibiting the overactivated immune system and promoting the recovery of pulmonary and other organs failure in severe COVID-19 cases.
  • This is Baylxs second IND clearance from FDA in three months.
  • In early June this year, Baylx also received the clearance of an IND from US FDA for the same product, BX-U001, in the treatment of rheumatoid arthritis (RA).

FUJIFILM Irvine Scientific to Exclusively Distribute Chemically Defined Substrate for Stem Cell Culture

Retrieved on: 
Tuesday, September 29, 2020
Biotechnology, Health, Science, Stem cells, Research, Branches of biology, Biology, Life sciences, Biotechnology, Cell biology, Stem cells, Developmental biology, Mesenchymal stem cell, Cellular differentiation, Cell culture, Chemically defined medium, Extracellular matrix

FUJIFILM Irvine Scientific, Inc., today announced that it has become the exclusive, worldwide distributor of cellnest, a recombinant peptide attachment substrate that provides optimal adhesion and proliferation of stem cells in chemically defined, animal component-free conditions.

Key Points: 
  • FUJIFILM Irvine Scientific, Inc., today announced that it has become the exclusive, worldwide distributor of cellnest, a recombinant peptide attachment substrate that provides optimal adhesion and proliferation of stem cells in chemically defined, animal component-free conditions.
  • Cellnest was designed and manufactured by FUJIFILM Corporation, joining its vast portfolio of solutions that support life science applications and therapeutic innovation.
  • Attachment substrates mimic the extracellular matrix (ECM), a complex and dynamic environment in which cells reside in vivo, in cell culture and allow for the adhesion, expansion, and potential differentiation of stem cells.
  • It is an ideal companion product to FUJIFILM Irvine Scientifics PRIME-XV portfolio of xeno-free and chemically defined media for stem cell culture, and is well suited for the attachment and growth of mesenchymal stem cells (MSCs).

Mesoblast Wins 2020 Fierce Biotech Innovation of the Year Award for remestemcel-L

Retrieved on: 
Tuesday, September 15, 2020
Branches of biology, Biology, Life sciences, Stem cells, Regenerative biomedicine, Mesoblast, Biotechnology, Mesenchymal stem cell, Prescription Drug User Fee Act, Bone marrow, Prochymal

The FDA has set a Prescription Drug User Fee Act (PDUFA) action date of September 30, 2020.

Key Points: 
  • The FDA has set a Prescription Drug User Fee Act (PDUFA) action date of September 30, 2020.
  • Remestemcel-L is an investigational therapy comprising culture-expanded mesenchymal stem cells derived from the bone marrow of an unrelated donor.
  • Mesoblast has a strong and extensive global intellectual property (IP) portfolio with protection extending through to at least 2040 in all major markets.
  • Mesoblast is completing Phase 3 trials for its product candidates for advanced heart failure and chronic low back pain.